Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer

Anthony Patterson, Richard E. Greenberg, Lamar Weems, Robert Bahnson, Zev Wajsman, Mervyn Israel, Trevor Sweatman, Denise Webber, Joseph Gulfo

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objectives. To assess in a pilot study the safety, tolerability, and technical feasibility of administering intravesical valrubicin immediately after transurethral resection of bladder tumors (TURBT) in patients with superficial bladder cancer and to evaluate the optimal dose of valrubicin and its systemic absorption.Methods. Twenty-two patients with recurrent or newly diagnosed Stage Ta or T1 transitional cell tumors received a single dose of 400 mg, 600 mg, or 800 mg of intravesical valrubicin immediately after TURBT. Four patients thought to be at high risk of recurrence were followed up with five additional doses of 800 mg valrubicin, given weekly.Results. The use of valrubicin after TURBT was generally well tolerated. Little evidence was found to suggest a direct relationship among the dose of valrubicin, the time between the end of TURBT and drug instillation, and the occurrence of most bladder symptoms. The most commonly reported adverse events included dysuria (77%), hematuria (59%), and urgency/frequency (23%). Pharmacokinetic analyses revealed that the mean systemic exposure to valrubicin and its metabolites depended on the extent of the TURBT and the damage to the bladder wall.Conclusions. The results of this study indicated that administration of valrubicin immediately after TURBT is feasible. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)232-235
Number of pages4
JournalUrology
Volume56
Issue number2
DOIs
StatePublished - Aug 1 2000

Fingerprint

valrubicin
Urinary Bladder Neoplasms
Drug Instillation
Urinary Bladder
Intravesical Administration
Dysuria
Hematuria

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. / Patterson, Anthony; Greenberg, Richard E.; Weems, Lamar; Bahnson, Robert; Wajsman, Zev; Israel, Mervyn; Sweatman, Trevor; Webber, Denise; Gulfo, Joseph.

In: Urology, Vol. 56, No. 2, 01.08.2000, p. 232-235.

Research output: Contribution to journalArticle

Patterson, Anthony ; Greenberg, Richard E. ; Weems, Lamar ; Bahnson, Robert ; Wajsman, Zev ; Israel, Mervyn ; Sweatman, Trevor ; Webber, Denise ; Gulfo, Joseph. / Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. In: Urology. 2000 ; Vol. 56, No. 2. pp. 232-235.
@article{cfdd479468074fca874c6caf884b53f6,
title = "Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer",
abstract = "Objectives. To assess in a pilot study the safety, tolerability, and technical feasibility of administering intravesical valrubicin immediately after transurethral resection of bladder tumors (TURBT) in patients with superficial bladder cancer and to evaluate the optimal dose of valrubicin and its systemic absorption.Methods. Twenty-two patients with recurrent or newly diagnosed Stage Ta or T1 transitional cell tumors received a single dose of 400 mg, 600 mg, or 800 mg of intravesical valrubicin immediately after TURBT. Four patients thought to be at high risk of recurrence were followed up with five additional doses of 800 mg valrubicin, given weekly.Results. The use of valrubicin after TURBT was generally well tolerated. Little evidence was found to suggest a direct relationship among the dose of valrubicin, the time between the end of TURBT and drug instillation, and the occurrence of most bladder symptoms. The most commonly reported adverse events included dysuria (77{\%}), hematuria (59{\%}), and urgency/frequency (23{\%}). Pharmacokinetic analyses revealed that the mean systemic exposure to valrubicin and its metabolites depended on the extent of the TURBT and the damage to the bladder wall.Conclusions. The results of this study indicated that administration of valrubicin immediately after TURBT is feasible. Copyright (C) 2000 Elsevier Science Inc.",
author = "Anthony Patterson and Greenberg, {Richard E.} and Lamar Weems and Robert Bahnson and Zev Wajsman and Mervyn Israel and Trevor Sweatman and Denise Webber and Joseph Gulfo",
year = "2000",
month = "8",
day = "1",
doi = "10.1016/S0090-4295(00)00654-3",
language = "English (US)",
volume = "56",
pages = "232--235",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer

AU - Patterson, Anthony

AU - Greenberg, Richard E.

AU - Weems, Lamar

AU - Bahnson, Robert

AU - Wajsman, Zev

AU - Israel, Mervyn

AU - Sweatman, Trevor

AU - Webber, Denise

AU - Gulfo, Joseph

PY - 2000/8/1

Y1 - 2000/8/1

N2 - Objectives. To assess in a pilot study the safety, tolerability, and technical feasibility of administering intravesical valrubicin immediately after transurethral resection of bladder tumors (TURBT) in patients with superficial bladder cancer and to evaluate the optimal dose of valrubicin and its systemic absorption.Methods. Twenty-two patients with recurrent or newly diagnosed Stage Ta or T1 transitional cell tumors received a single dose of 400 mg, 600 mg, or 800 mg of intravesical valrubicin immediately after TURBT. Four patients thought to be at high risk of recurrence were followed up with five additional doses of 800 mg valrubicin, given weekly.Results. The use of valrubicin after TURBT was generally well tolerated. Little evidence was found to suggest a direct relationship among the dose of valrubicin, the time between the end of TURBT and drug instillation, and the occurrence of most bladder symptoms. The most commonly reported adverse events included dysuria (77%), hematuria (59%), and urgency/frequency (23%). Pharmacokinetic analyses revealed that the mean systemic exposure to valrubicin and its metabolites depended on the extent of the TURBT and the damage to the bladder wall.Conclusions. The results of this study indicated that administration of valrubicin immediately after TURBT is feasible. Copyright (C) 2000 Elsevier Science Inc.

AB - Objectives. To assess in a pilot study the safety, tolerability, and technical feasibility of administering intravesical valrubicin immediately after transurethral resection of bladder tumors (TURBT) in patients with superficial bladder cancer and to evaluate the optimal dose of valrubicin and its systemic absorption.Methods. Twenty-two patients with recurrent or newly diagnosed Stage Ta or T1 transitional cell tumors received a single dose of 400 mg, 600 mg, or 800 mg of intravesical valrubicin immediately after TURBT. Four patients thought to be at high risk of recurrence were followed up with five additional doses of 800 mg valrubicin, given weekly.Results. The use of valrubicin after TURBT was generally well tolerated. Little evidence was found to suggest a direct relationship among the dose of valrubicin, the time between the end of TURBT and drug instillation, and the occurrence of most bladder symptoms. The most commonly reported adverse events included dysuria (77%), hematuria (59%), and urgency/frequency (23%). Pharmacokinetic analyses revealed that the mean systemic exposure to valrubicin and its metabolites depended on the extent of the TURBT and the damage to the bladder wall.Conclusions. The results of this study indicated that administration of valrubicin immediately after TURBT is feasible. Copyright (C) 2000 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033943168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033943168&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(00)00654-3

DO - 10.1016/S0090-4295(00)00654-3

M3 - Article

VL - 56

SP - 232

EP - 235

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -